Baiqing essential oil composition for treating blood deficiency and wind dryness syndrome of chronic eczema

Abstract

The invention provides a Baiqing essential oil composition for treating blood deficiency and wind dryness syndrome of chronic eczema, and belongs to the field of biological medicine. The white tea essential oil composition comprises sweet wormwood essential oil and white tea essential oil, the mass ratio of the artemisia apiacea essential oil to the white tea essential oil is (1-5): 1. The Baiqing essential oil emulsifiable paste is guided by the theory of traditional Chinese medicine and follows the theory and principle of prescription compatibility, the artemisia apiacea is used as the monarch for clearing heat and expelling evil, the white tea is used as the minister for eliminating dampness and treating sores, and the effects of resisting inflammation and relieving itching are jointly achieved. Vaseline is used as a matrix, oily substances are used for nourishing and moistening the skin and enhancing the efficacy, and the traditional Chinese medicine composition has an excellent effect on treating the blood deficiency and wind dryness syndrome of chronic eczema, especially the blood deficiency and wind dryness syndrome of mild and moderate chronic eczema. Compared with vaseline or an artemisia apiacea / white tea essential oil mixture which is independently used, the white tea and green tea essential oil emulsifiable paste has a better treatment effect and plays a synergistic interaction role. The invention provides a new clinical basis for subsequent traditional Chinese medicine treatment of chronic eczema (blood deficiency and wind dryness syndrome).

Description

Technical Field

[0001] This invention belongs to the field of biomedicine, specifically relating to a white peony essential oil composition for treating chronic eczema with blood deficiency and wind dryness syndrome. Background Technology

[0002] Clinically, eczema is characterized by polymorphic skin lesions, symmetrical distribution, exudative tendency, itching, recurrent attacks, and a tendency to become chronic. Based on the characteristics of the skin lesions, eczema can be divided into acute, subacute, and chronic phases. Chronic eczema develops from acute and subacute eczema, or it can initially present as chronic due to persistent mild irritation. Compared to acute eczema, which presents with dense, millet-sized papules, papulovesicles, small vesicles, erosions, and significant exudation on an erythematous base; and subacute eczema, which presents with dark red patches and papules, scales, crusts, mild infiltration, and intense itching, chronic eczema is characterized by lichenification, thickened infiltration, rough surface, often accompanied by scratch marks, crusts, and pigmentation changes. Chronic eczema is difficult to cure, causes severe itching, and is prone to recurrence, significantly impacting patients' studies and work.

[0003] In recent years, international treatment of chronic eczema has made some progress. Treatment guidelines published by authoritative organizations such as the European and American Dermatological Societies recommend the use of topical corticosteroids and topical immunomodulators (such as tacrolimus and pimecrolimus) for external application. Glucocorticoids, as the first-line drug of choice for topical treatment of chronic eczema, have good anti-inflammatory and immunosuppressive effects, effectively relieving skin lesions and itching. However, long-term use of topical corticosteroids can lead to adverse reactions such as skin atrophy and thinning, and telangiectasia. Non-steroidal topical immunomodulators also have good anti-inflammatory and immunomodulatory effects. For example, tacrolimus achieves its anti-inflammatory effect by inhibiting T lymphocyte activation and is a representative drug of calcineurin inhibitors. However, it is prone to causing skin irritation symptoms such as burning and itching in the initial stages of use.

[0004] Traditional Chinese medicine (TCM) research on eczema can be found in records from the *Huangdi Neijing Suwen* (The Yellow Emperor's Inner Classic - Basic Questions): "All painful, itchy sores belong to the heart; all dampness and swelling belong to the spleen." The *Suwen* also records, "It is pervasive. The heat cannot be dispelled." The *Wai Ke Zheng Zong* (Orthodox Manual of External Medicine) states, "Eczema is caused by the accumulation of wind and dampness, which, over time, causes itching like tinea." In traditional TCM theory, the onset of eczema is closely related to wind, dampness, and heat. Prolonged damp sores lead to the accumulation of damp heat, which in turn causes dryness, damaging yin and resulting in chronic eczema. Zhang Zhongjing of the Han Dynasty pointed out in *Jinkui Yaolue* (Essential Prescriptions of the Golden Chamber): "For pervasive sores, Coptis chinensis powder is the main treatment." He was the first to propose a TCM treatment for this disease. Chao Yuanfang of the Sui Dynasty recorded in *Zhu Bing Yuan Hou Lun* (Treatise on the Causes and Symptoms of Various Diseases): "All chronic sores are caused by wind and dampness, with damp heat clashing, hence sores appear on the head, face, and body." "It clearly points out that wind, dampness, and heat are the three pathogenic factors, laying the initial foundation for the etiology and pathogenesis of this disease. Chen Shigong of the Ming Dynasty, in his *Orthodox Manual of Surgery*, supplemented the cause with improper diet and internal damp-heat, and proposed the external treatment method of clam powder powder. Wu Qian of the Qing Dynasty, in his *Golden Mirror of Medicine*, described it as: 'This disease initially resembles scabies, with constant itching, spreading relentlessly, causing yellow oozing fluid when scratched, resulting in patches of dampness, caused by wind affecting the heart and spleen.' This not only provides a detailed description of the clinical symptoms of eczema but also organically combines internal and external causes. In recent years, with the deepening research into the treatment mechanisms of traditional Chinese medicine, the positive effects of Chinese herbal components on improving skin barrier function and reducing inflammatory responses have been confirmed. Traditional Chinese medicine treatment for eczema has shown certain advantages."

[0005] Chinese patent application CN 113662978A discloses an artemisia annua essential oil, white tea essential oil, and their combination for treating eczema. The patent states that the combination of artemisia annua essential oil and white tea essential oil can treat eczema with better results. However, this patent only targets the treatment of common eczema. Chronic eczema due to blood deficiency and wind-dryness is a relatively difficult-to-treat chronic eczema. Due to its prolonged course and recurring nature, patients with chronic eczema due to blood deficiency and wind-dryness often experience a vicious cycle of long-term itching → insufficient sleep → emotional anxiety, causing the body to be in a chronic, mild inflammatory stress state. Simultaneously, prolonged illness depletes yin and blood, leading to blood deficiency that fails to nourish the skin, resulting in internal wind-dryness, further exacerbating the damage to the skin barrier and transepidermal water loss. Unlike common eczema, which is characterized by a superficial excess of "dampness, heat, and blood stasis," this condition is characterized by "deficiency in the root and excess in the branch." Treatment must address the root cause by nourishing blood, moistening dryness, and relieving itching, while avoiding excessive use of bitter-cold drying or pungent-warm dispersing herbs that could further damage yin and blood. Therefore, the selection of prescriptions and medications faces numerous constraints. Furthermore, the skin lesions often exhibit lichenification and thickened keratinization, resulting in poor local drug penetration. Topical preparations struggle to achieve effective concentrations, and oral antihistamines only provide temporary relief from itching, failing to correct the underlying pathogenesis of blood deficiency and wind-dryness. Consequently, compared to common eczema, chronic eczema due to blood deficiency and wind-dryness has a longer treatment cycle and a higher recurrence rate, and is considered one of the clinically refractory skin diseases. The effectiveness of medications used to treat common eczema in treating chronic eczema due to blood deficiency and wind-dryness is unpredictable. Summary of the Invention

[0006] The purpose of this invention is to provide a white peony essential oil composition for treating chronic eczema with blood deficiency and wind dryness syndrome.

[0007] The present invention provides a white tea essential oil composition for treating chronic eczema, comprising artemisia annua essential oil and white tea essential oil; wherein the mass ratio of artemisia annua essential oil to white tea essential oil is (1-5):1.

[0008] Furthermore, the aforementioned white tea essential oil composition includes artemisia annua essential oil and white tea essential oil; the mass ratio of artemisia annua essential oil to white tea essential oil is 4:1.

[0009] Furthermore, the aforementioned white peony essential oil composition also includes petrolatum.

[0010] Furthermore, the aforementioned white tea essential oil composition is a cream prepared from artemisia annua essential oil, white tea essential oil, and petrolatum; the mass percentage of artemisia annua essential oil and white tea essential oil in the cream is 1-10%.

[0011] Furthermore, the aforementioned white tea essential oil composition is a cream prepared from artemisia annua essential oil, white tea essential oil, and petrolatum; the mass percentage of artemisia annua essential oil and white tea essential oil in the cream is 5%.

[0012] The present invention also provides a method for preparing the aforementioned white tea essential oil composition, which includes the following steps: mixing artemisia essential oil, white tea essential oil and petrolatum to obtain the composition.

[0013] The present invention also provides the use of the aforementioned white peony essential oil composition in the preparation of a medicament for treating chronic eczema.

[0014] Furthermore, the aforementioned drug is for treating chronic eczema due to blood deficiency and wind-dryness syndrome.

[0015] Furthermore, the chronic eczema is mild to moderate chronic eczema.

[0016] Furthermore, the drug is a moisturizing, anti-inflammatory, and / or anti-allergic drug.

[0017] The chronic eczema of blood deficiency and wind-dryness syndrome is more difficult to treat than ordinary eczema. Previous research by the inventors used a mixture of artemisia annua essential oil and white tea essential oil (4:1 by weight) to treat chronic eczema of blood deficiency and wind-dryness syndrome, but the results were unsatisfactory, far less effective than the white artemisia annua essential oil cream prepared using petrolatum as a base in this invention.

[0018] The present invention achieves the following beneficial effects through a specific technical solution: This invention, a white tea / artemisia essential oil cream, is guided by traditional Chinese medicine theory and follows the principles of formula compatibility. Artemisia annua is the principal ingredient, clearing heat and expelling pathogens, while white tea is the secondary ingredient, dispelling dampness and healing sores, working together to achieve anti-inflammatory and antipruritic effects. Furthermore, petrolatum is used as a base, with oily substances nourishing and moisturizing the skin, enhancing its efficacy. It is particularly effective in treating mild to moderate cases of chronic eczema with blood deficiency and wind-dryness syndrome. At the same dosage, the white tea / artemisia essential oil cream demonstrates better therapeutic effects compared to using petrolatum alone or an Artemisia annua / white tea essential oil mixture, exhibiting a synergistic effect. This invention provides new clinical evidence for the subsequent treatment of chronic eczema (blood deficiency and wind-dryness syndrome) with traditional Chinese medicine.

[0019] Obviously, based on the above description of the present invention, and according to common technical knowledge and conventional methods in the field, various other modifications, substitutions or alterations can be made without departing from the basic technical concept of the present invention.

[0020] The following detailed embodiments further illustrate the above-described content of the present invention. However, this should not be construed as limiting the scope of the present invention to the following embodiments. All technologies implemented based on the above-described content of the present invention fall within the scope of the present invention. Attached Figure Description

[0021] Figure 1 These are before-and-after photos of patients in the matrix group.

[0022] Figure 2 These are before-and-after photos of patients in the control group.

[0023] Figure 3 Photos showing the before and after treatment for the 1% group of patients.

[0024] Figure 4 Photos showing the before and after treatment for the 3% group of patients.

[0025] Figure 5 Photos showing the before and after treatment for 5% of patients.

[0026] Figure 6 For the purpose of studying flowcharts.

[0027] Figure 7 Images of skin lesions on the back of mice after the last administration of the drug.

[0028] Figure 8 The images show the H&E staining results of the skin of mice in each group, magnified at 20X.

[0029] Figure 9 The images show the immunohistochemical staining results of IL-6, IL-1β, and TNF-α in six groups of mice. Detailed Implementation

[0030] The raw materials and equipment used in this invention are all known products, obtained by purchasing commercially available products.

[0031] Example 1: Preparation of the white peony essential oil cream of the present invention 1. Preparation of Artemisia annua essential oil The artemisia annua essential oil used in this embodiment is a commercially available product (Mujiuye (Shanghai) Technology Co., Ltd.), but it can also be prepared using the following method: Fresh young shoots of Artemisia annua L., a plant of the Asteraceae family, were collected from Henan Province. The leaves were taken, dried, and cut into small pieces. They were then placed in a distillation apparatus, and distilled water was added at a material-to-liquid ratio of 1:(0.5-2). After soaking, distillation was started for 60-90 minutes to obtain a mixture of essential oil hydrosol. The mixture was then separated using a separator to obtain Artemisia annua essential oil.

[0032] 2. Preparation of white tea essential oil The white tea essential oil used in this embodiment is a commercially available product (Mujiuye (Shanghai) Technology Co., Ltd.), but it can also be prepared using the following method: Fresh buds of *Camellia sinensis* (L.) O. Ktze, a plant belonging to the Theaceae family, were collected from the Pu'er region of Yunnan Province. The buds were neatly spread out in a shaded indoor environment to a thickness of 3-5 cm, with the temperature controlled at 30-35℃ and the humidity at 50%-60%. The leaves were withered until a weight loss of 50%-60% was achieved, and then dried in a dryer at 100-120℃ for 20-40 minutes. The dried tea leaves were then pulverized and subjected to supercritical CO2 fluid extraction to obtain white tea essential oil.

[0033] 3. Preparation of White Green Essential Oil Cream Artemisia annua essential oil and white tea essential oil were mixed at a mass ratio of 4:1 to obtain white tea essential oil. The base petrolatum was then mixed with the white tea essential oil to obtain a white tea essential oil cream with a mass percentage of 1%.

[0034] Example 2: Preparation of the white peony essential oil cream of the present invention 1. Preparation of Artemisia annua essential oil The artemisia annua essential oil used in this embodiment is a commercially available product (Mujiuye (Shanghai) Technology Co., Ltd.), or it can be prepared according to the method described in Example 1.

[0035] 2. Preparation of white tea essential oil The white tea essential oil used in this embodiment is a commercially available product (Mujiuye (Shanghai) Technology Co., Ltd.), or it can be prepared according to the method described in Example 1.

[0036] 3. Preparation of White Green Essential Oil Cream Artemisia annua essential oil and white tea essential oil were mixed at a mass ratio of 4:1 to obtain white tea essential oil. The base petrolatum was then mixed with the white tea essential oil to obtain a white tea essential oil cream with a mass percentage of 3%.

[0037] Example 3: Preparation of the white peony essential oil cream of the present invention 1. Preparation of Artemisia annua essential oil The artemisia annua essential oil used in this embodiment is a commercially available product (Mujiuye (Shanghai) Technology Co., Ltd.), or it can be prepared according to the method described in Example 1.

[0038] 2. Preparation of white tea essential oil The white tea essential oil used in this embodiment is a commercially available product (Mujiuye (Shanghai) Technology Co., Ltd.), or it can be prepared according to the method described in Example 1.

[0039] 3. Preparation of White Green Essential Oil Cream Artemisia annua essential oil and white tea essential oil were mixed at a mass ratio of 4:1 to obtain white tea essential oil. The base petrolatum was then mixed with the white tea essential oil to obtain a white tea essential oil cream with a mass percentage of 5%.

[0040] The following specific experimental examples demonstrate the beneficial effects of the present invention.

[0041] Experimental Example 1: Clinical observation of the efficacy of Baiqing essential oil cream on mild to moderate chronic eczema with blood deficiency and wind-dryness syndrome. 1. Materials and Methods 1.1 General Information This study included 145 patients with chronic eczema due to blood deficiency and wind dryness who were admitted to the Department of Dermatology of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, affiliated to Shanghai University of Traditional Chinese Medicine, from March 2023 to December 2023. They were divided into four groups according to different administration methods: matrix group (n=29), control group (n=29), 1% group (n=29), 3% group (n=29) and 5% group (n=29).

[0042] 1.2 Diagnostic criteria 1.2.1 Western Medicine Diagnostic Criteria The diagnostic criteria for Western medicine were determined with reference to the "Integrated Traditional Chinese and Western Medicine Dermatology and Venereology" (New Century Third Edition); Chronic eczema: The lesions may be conical, rice-grain-sized, grayish-brown papules that may merge into patches, become infiltrated and thickened, and show increased pigmentation. It may have acute exacerbations and a tendency to ooze.

[0043] 1.2.2 Traditional Chinese Medicine Diagnostic Criteria The diagnostic criteria for TCM syndromes are determined with reference to the "Integrated Traditional Chinese and Western Medicine Dermatology and Venereology" (New Century Third Edition). If the patient has the following main symptoms and also has one or more additional symptoms, the patient can be diagnosed with this syndrome.

[0044] Blood deficiency and wind-dryness syndrome: The main symptoms are long course of disease, recurrent attacks, dark skin lesions or pigmentation, severe itching, or rough and thickened skin lesions.

[0045] Concurrent symptoms may include dry mouth without thirst, poor appetite, and abdominal distension. The patient's tongue is pale with a white coating, and the pulse is weak and thready.

[0046] 1.3 Discharge Standards 1.3.1 Inclusion criteria: Patients with mild to moderate eczema who meet the diagnostic and differentiation criteria of traditional Chinese medicine and Western medicine for chronic eczema (blood deficiency and wind dryness syndrome); aged ≥18 years and ≤80 years, gender not limited; EASI score <20.

[0047] 1.3.2 Exclusion criteria: Patients with allergy to any component of the drug; pregnant women, women planning to become pregnant, or breastfeeding women; patients who are alcoholics or undergoing drug rehabilitation; any clinically significant laboratory test results that the investigator believes may affect patient safety; patients with liver or kidney dysfunction, or serious diseases such as cardiovascular, cerebrovascular, or hematopoietic system diseases, or mental illness; patients with interfering factors that affect drug absorption, distribution, metabolism, and excretion; patients who have used steroid drugs within 2 weeks prior to treatment, and / or have taken oral antihistamines or used topical steroid preparations within 1 week prior to treatment.

[0048] 1.3.3 Exclusion Criteria Subjects will be excluded if they violate the inclusion criteria or meet the exclusion criteria during the trial period; if they use drugs or other treatments that are prohibited in this study during the trial observation period; or if they have poor compliance.

[0049] 1.3.4 Termination Criteria Significant deviations occurred in the design or implementation of the clinical study, making it difficult to assess efficacy; adverse events or serious adverse events occurred during the trial; or certain comorbidities or complications occurred during the clinical trial.

[0050] 1.3.5 Shedding Criteria During clinical trials, the condition of participants may continue to deteriorate and dangerous events may occur. The decision to terminate the clinical trial should be made by the physician. Participants who withdraw during the trial without explanation or due to personal reasons and are lost to follow-up should be reported.

[0051] 1.4 Methods Before treatment, all patients received basic treatment, which included introducing the causes, inducing factors, aggravating factors, treatment, and prognosis of chronic eczema with blood deficiency and wind dryness syndrome to improve their understanding of this syndrome. The treatment also included explanations of prevention and care for chronic eczema with blood deficiency and wind dryness syndrome, such as how to relieve itching on the affected area, maintaining a light diet, avoiding spicy and irritating foods and seafood, engaging in moderate exercise, reducing contact with irritating products such as hand sanitizer, limiting bathing frequency and duration to no more than 3 times per week for half an hour each time, maintaining a suitable bathing temperature (36-39 degrees Celsius in summer and 40-45 degrees Celsius in winter), avoiding alkaline bath products or soaps during bathing, and using moisturizing lotion (Yuze Moisturizing Lotion) after bathing.

[0052] Following basic treatment, patients in the matrix group received topical application of petrolatum preparations, while patients in the control group received topical application of hydrocortisone butyrate (Eucerin). Patients in the 1% group received topical application of 1% white peony cream prepared in Example 1, patients in the 3% group received topical application of 3% white peony cream prepared in Example 2, and patients in the 5% group received topical application of 5% white peony cream prepared in Example 3. The application method for all groups was as follows: take a 1 cm length of cream and apply it to approximately 10 square centimeters. 2 For lesions of varying sizes. Gently spread the product to ensure close contact with the skin, and apply to all affected areas of the body twice daily. One course of treatment lasts 4 weeks.

[0053] 1.5 Observation Indicators (1) Eczema Area and Severity Index (EASI) was used to observe the area and severity of chronic eczema before treatment and after the 4th week of treatment, and to evaluate the patients’ EASI scores.

[0054] (2) The Visual Analogue Scale (VAS) and the Dermoatology Life Quality Index (DLQI) were collected in the form of questionnaires before treatment and after the fourth week of treatment. First, the outpatient doctor explained the purpose of the study to the patient, and then the patient completed the itch severity and quality of life scores on his / her own. If the scores decreased after treatment, it indicated that the treatment was effective.

[0055] (3) Transepidermal water loss (TEWL): TEWL values ​​at the skin lesions were measured using a TM300 transepidermal water loss meter before treatment and after the 4th week of treatment. Patients were instructed to wash their skin with warm water overnight and wipe it clean the day before each measurement. Cream use was suspended before measuring TEWL values ​​on the day of measurement. The measurement lasted 30 seconds, and the ambient temperature was maintained at 22-25℃, with a relative humidity of 35%-55% during the measurement process.

[0056] (4) Safety indicators were measured before treatment and after the 4th week of treatment, including vital signs, blood routine, liver and kidney function, urine routine and assessment of adverse events.

[0057] 1.6 Therapeutic Indicators Comprehensive efficacy assessment According to the efficacy evaluation criteria in the "Guiding Principles for Clinical Research of New Traditional Chinese Medicines" (2002): Efficacy Index (skin lesion improvement rate) = [(EASI score before treatment - EASI score after treatment) / EASI score before treatment] × 100%. The degree of efficacy in treating skin lesions is judged based on the change in the patient's score before and after treatment, and is divided into 4 levels: Clinical cure: This means that all skin lesions have subsided, symptoms have disappeared, and the efficacy index is ≥95%; Significant effect: meaning that most of the patient's skin lesions have subsided and symptoms have been significantly relieved, with a efficacy rate of 95% > efficacy index ≥ 70%; Effective: This means that the patient's skin lesions have partially subsided, and the symptoms have improved compared to before, with a efficacy index of ≥50% (70% > efficacy index). Ineffective; meaning the patient's skin lesions do not significantly improve, symptoms do not lessen, or skin lesions even increase, with an efficacy index of <50%.

[0058] Effective rate = (number of cured patients + number of patients with significant improvement) / total number of patients in the same group × 100%.

[0059] Effectiveness rate = (number of cured patients + number of patients with significant improvement + number of patients with effective results) / total number of patients in the same group × 100%.

[0060] 1.7 Statistical Analysis All data analyses in this invention will be performed using GraphPad Prism 9 software. Quantitative data conforming to a normal distribution are expressed as mean ± standard deviation; data not conforming to a normal distribution are expressed as median and interquartile range (P25~P75). The Shapiro-Wilk (SW) test is used for normality testing. Categorical data are expressed as number of cases (percentage / component ratio). For comparisons of multiple groups of normally distributed quantitative data, one-way ANOVA is used; pairwise comparisons are performed using the Tukey method; for data not conforming to normality, the Kruskal-Wallis (KW) test is used; and pairwise comparisons are performed using Fisher's exact test. For comparisons of differences between groups of categorical variables, the chi-square test or Fisher's exact test is used; pairwise comparisons are corrected using Bonferroni. All statistical methods use two-tailed tests, with a significance level of α=0.05. A p-value < 0.05 is considered statistically significant.

[0061] 2. Research Results 2.1 General Clinical Data Two male patients were included in the matrix group, one male patient in the 1% group, and two male patients in the 3% group. These patients withdrew from the trial after developing folliculitis one week into treatment. Ultimately, 27 patients were included in the matrix group, 29 in the control group, 28 in the 1% group, 27 in the 3% group, and 29 in the 5% group. There were no statistically significant differences in age, disease duration, and pre-treatment EASI, VAS, DLQI scores, and TEWL data among the five groups (P > 0.05), therefore the five groups were comparable.

[0062] 2.2 Evaluation of clinical efficacy in each group Table 1 shows the efficacy evaluation of each group after 4 weeks of treatment.

[0063] The total effective rates of the control group, 1% group, 3% group, and 5% group were all significantly different from those of the matrix group, indicating that the total effective rates of the control group, 1% group, 3% group, and 5% group were all superior to those of the matrix group. The total effective rate of the 5% group was not significantly different from that of the control group, indicating that the clinical total effective rate of the 5% group was similar to that of the control group. Furthermore, the total effective rate of the 5% group was significantly different from that of the 1% group and the 3% group, indicating that the total effective rate of the 5% group was superior to that of the 1% group and the 3% group. The total effective rates of the 1% group and the 3% group were similar.

[0064] The effective rates of the control group, 1%, 3%, and 5% groups were all statistically significant compared to the matrix group, indicating that the effective rates of the control group, 1%, 3%, and 5% groups were superior to those of the matrix group. The effective rate of the 5% group was significantly different from that of the control group, indicating that the clinical effective rate of the 5% group was superior to that of the control group. The clinical effective rates of the 3% and 1% groups were similar to those of the control group. Furthermore, the effective rate of the 5% group was superior to that of the 1% and 3% groups.

[0065] The above results indicate that the clinical efficacy of 5% styrax essential oil cream in treating patients with chronic eczema due to blood deficiency and wind-dryness syndrome is the best compared to commonly used medications for chronic eczema, such as hydrocortisone butyrate ointment, 1% styrax essential oil cream, and 3% styrax essential oil cream. Styrax essential oil cream exhibits a concentration-dependent trend; the higher the concentration, the better the effect.

[0066] Table 1. Statistical analysis of efficacy evaluation in each group after treatment. 2.3 EASI score for efficacy evaluation (1) Comparison of EASI scores before and after treatment in 5 groups Table 2 shows the EASI scores before and after treatment. There was no statistically significant difference in EASI scores before and after treatment in the matrix group; however, there were statistically significant differences in EASI scores before and after treatment in the control group, 1% group, 3% group, and 5% group.

[0067] Table 2. Changes in EASI before and after treatment [M(Q1,Q3), points] (2) Comparison of EASI scores before and after treatment in 5 groups Table 3 shows the comparison of EASI scores before and after treatment. Pairwise comparisons were performed between the five groups before and after 4 weeks of treatment to identify statistically significant differences between the matrix group and the control group, the 1% group, the 3% group, and the 5% group. There were no statistically significant differences between the three different concentration groups and the control group. A statistically significant difference was found between the 5% group and the 1% group.

[0068] Table 3. Pairwise comparison of EASI differences before and after treatment in each group This indicates that the control group, different concentration groups, and the matrix group all significantly alleviated the clinical symptoms of patients with chronic eczema due to blood deficiency and wind dryness.

[0069] 2.4 VAS score as an efficacy indicator (1) Comparison of VAS before and after treatment in 5 groups Table 4 shows the VAS scores before and after treatment. There was no statistically significant difference in VAS scores before and after treatment in the matrix group; however, there were statistically significant differences in VAS scores before and after treatment in the control group, 1% group, 3% group, and 5% group.

[0070] Table 4. Changes in VAS scores before and after treatment in each group [M(Q1,Q3), scores] (2) Comparison of VAS scores before and after treatment in 5 groups Table 5 shows the comparison of VAS score differences before and after treatment. Pairwise comparisons of VAS score differences between the five groups before and after 4 weeks of treatment revealed statistically significant differences between the matrix group and the control group, the 1% group, the 3% group, and the 5% group. No statistically significant differences were found between the other groups.

[0071] Table 5. Pairwise comparison of VAS score differences before and after treatment in each group This indicates that the control group, different concentration groups, and the matrix group can all effectively relieve the skin itching symptoms of patients with chronic eczema due to blood deficiency and wind dryness.

[0072] 2.5 DLQI score as an efficacy indicator (1) Comparison of DLQI before and after treatment in 5 groups Table 6 shows the DLQI scores before and after treatment. There was no statistically significant difference in DLQI scores before and after treatment in the matrix group; however, there were statistically significant differences in VAS scores before and after treatment in the control group, 1% group, 3% group, and 5% group.

[0073] Table 6. Changes in DLQI before and after treatment [M(Q1,Q3), points] (2) Pairwise comparison of DLQI differences before and after treatment in the 5 groups Table 7 shows the comparison of DLQI differences after treatment. Pairwise comparisons of VAS score differences between the five groups before and after 4 weeks of treatment revealed statistically significant differences between the matrix group and the control group, the 1% group, the 3% group, and the 5% group. No statistically significant differences were found between the other groups.

[0074] Table 7. Pairwise comparison of DLQI differences among groups after treatment This indicates that the control group, different concentration groups, and the matrix group have good efficacy in improving the quality of life of patients with chronic eczema due to blood deficiency and wind dryness.

[0075] 2.6 TEWL efficacy indicators at the skin lesion site (1) Comparison of TEWL at the lesion sites before and after treatment in 5 groups Table 8 shows the TEWL scores before and after treatment. Comparisons of TEWL scores at the lesion sites before and after treatment were made in the matrix group, 1% group, 3% group, and 5% group. The results showed that P<0.01, indicating statistically significant differences in TEWL scores at the lesion sites before and after treatment in all four groups.

[0076] Table 8. Changes in TEWL at the Lesion Site Before and After Treatment [M (Q1, Q3)] (2) Pairwise comparison of the TEWL difference at the lesion sites before and after treatment in the 5 groups Table 9 shows the comparison of TEWL scores at the lesion sites before and after treatment. Pairwise comparisons were performed on the TEWL scores of the five groups before and after 4 weeks of treatment. For the matrix group -3% group, P < 0.05; for the matrix group -5% group, P < 0.01, the differences were statistically significant. For the matrix group - control group and the matrix group -1% group, P > 0.05, the differences were not statistically significant. For the control group -3% group and the control group -5% group, P < 0.01; for the control group -1% group, P > 0.05, the differences were not statistically significant. For the 1% group -3% group and the 1% group -5% group, P < 0.01; for the 3% group -5% group, P < 0.05, the differences were statistically significant.

[0077] Table 9. Pairwise comparison of TEWL differences at skin lesions in each group after treatment. The results indicate that both the matrix group and different concentration groups can reduce the TEWL level in the lesion area, achieving a moisturizing effect, with the 5% white sage oil cream showing the best effect.

[0078] 2.7 Safety Evaluation No significant abnormalities were found in vital signs, blood routine, liver and kidney function, urinalysis, and urine pregnancy test (for female patients) in either the treatment or control group.

[0079] 2.8 Clinical control diagram 2.8.1 Matrix Photos of patients in the matrix group before and after treatment are shown below. Figure 1 Four weeks after treatment, the erythema at the skin lesion site of patients in the matrix group worsened, epidermal peeling decreased slightly, and there was no significant difference in the level of papules and the degree of lichenification.

[0080] 2.8.2 Control Group Photos of the control group patients before and after treatment are shown below. Figure 2 After 4 weeks of treatment, the control group patients showed a reduction in the extent of skin lesions, a decrease in the number of papules, a slight reduction in epidermal exfoliation, and no significant improvement in the degree of lichenification.

[0081] 2.8.3 1% group Photos of the 1% group of patients before and after treatment are shown below. Figure 3 After 4 weeks of treatment, the 1% group of patients showed a reduction in the extent of skin lesions, a decrease in erythema, a slight reduction in epidermal peeling, a mild improvement in the degree of lichenification, and a small amount of pigmentation.

[0082] 2.8.4 3% group Photos of the 3% group of patients before and after treatment are shown below. Figure 4 After 4 weeks of treatment, the 3% of patients showed a reduction in the extent of skin lesions, a decrease in erythema, a reduction in the degree of induration / papules, a slight reduction in epidermal exfoliation, and a mild improvement in the degree of lichenification.

[0083] 2.8.5 5% group Photos of 5% of patients before and after treatment are shown below. Figure 5 After 4 weeks of treatment, 5% of patients showed significant reduction in erythema, lesion size, number of papules, epidermal exfoliation, and lichenification, with a small amount of pigmentation observed.

[0084] 3. Results Analysis This invention has found that white peony essential oil cream can effectively treat mild to moderate chronic eczema with blood deficiency and wind dryness syndrome. It can significantly improve the patient's skin lesions, relieve the patient's itching, improve the patient's quality of life, and rebuild the patient's skin barrier.

[0085] Experiment Example 2: Effects of Baiqing essential oil cream on DNCB-induced mouse dermatitis model and related immune indicators 1. Materials and Methods 1.1 Laboratory Animals Healthy male Balb / c mice, SPF grade, 10 weeks old, with a body weight of about 21±2 g, were provided by Beijing Vital River Laboratory Animal Technology Co., Ltd. [Certificate of Conformity: SCXK(Beijing) 2016-0011; License: SYXK(Shanghai) 2020-0009]. All experimental animals were housed in the SPF-level environment of the Experimental Animal Center of Shanghai University of Traditional Chinese Medicine, at a temperature of 25±2°C and a humidity of 40% - 50% (Ethical Approval Number: PZSHUTCM2302250001).

[0086] 1.2 Experimental drugs (1)Drugs for model establishment Matrix solution: Prepared according to the volume ratio of acetone to olive oil of 4:1. Add 20 ml of olive oil to 80 ml of acetone and mix well. Sensitizer: Dissolve 0.5 g of DNCB in 50 ml of acetone:olive oil = 4:1 (volume ratio) mixed solution, and mix well to obtain 1% concentration of DNCB. Store it in a cool, dark, and well-ventilated place for later use. Excitant: Add 20 ml of 1% DNCB solution to 20 ml of acetone:olive oil = 4:1 (volume ratio) mixed solution, and mix well to obtain 0.5% concentration of DNCB. Store it in a cool, dark, and well-ventilated place for later use.

[0087] (2)Topical drugs Hydrocortisone butyrate ointment (Tianjin KingYork Pharmaceutical Co., Ltd., National Drug Approval Number: H10940095); Artemisia annua essential oil and white tea essential oil were purchased from Mujiuye (Shanghai) Technology Co., Ltd. The batch number of Artemisia annua essential oil is XYJY0069, and the batch number of white tea essential oil is XYJY0037. Artemisia annua essential oil and white tea essential oil were mixed in a mass ratio of 4:1 to obtain white - green essential oil, and then mixed with vaseline to prepare a cream of a certain concentration (the concentration of white - green essential oil is 1%, 3%, and 5%, prepared according to the methods of Examples 1 - 3). When treating, take a small amount of ointment the size of a mung bean and evenly apply a thin layer on the skin lesion, and store it in a 4°C refrigerator for later use.

[0088] 1.3 Experimental methods (1)Experimental grouping Forty - two BALB / c mice were randomly divided into six groups, including a blank group, a model group, a control group, a 1% group, a 3% group, and a 5% group, with 7 mice in each group.

[0089] (2)Model establishment and intervention Preparation before model establishment: One day before the experiment, depilate the back of each group of mice using depilatory cream, with an area of about 3×3 cm 2 .

[0090] Model preparation: Except for the blank group, mice in other groups were sensitized by applying 1% DNCB solution to the hairless area on the back and the inner and outer sides of the right ear (100 μl and 20 μl respectively) once a day for 3 consecutive days. Starting from day 8, 0.5% DNCB solution was applied to the back and the inner and outer sides of the right ear for challenge. At the same time, a mixture of acetone and olive oil in a volume ratio of 4:1 was applied to the left ear. The challenge was performed once every other day for a total of 5 times.

[0091] Intervention method: Starting from day 8, the positive drug group was given 0.1g of hydrocortisone butyrate ointment applied to the back and right ear of mice, while the 1%, 3%, and 5% white peony oil ointment groups were given different concentrations of ointment applied to the back and right ear of mice, once a day for 10 consecutive days.

[0092] Experimental research process as follows Figure 6 As shown.

[0093] (3) Detection indicators Auricular hypersensitivity score After the last administration, the right ear of the mice was scored based on edema, erythema, and scratch marks. The scoring criteria are shown in Table 10.

[0094] Table 10. Scoring criteria for auricular allergies Skin lesions on the back of mouse B A photograph of the skin on the back was taken after the last administration of the drug.

[0095] C mouse spleen index Mice were euthanized by cervical dislocation after weighing. Their spleens were harvested, photographed, and weighed (mg). The spleen index was calculated. Spleen index = spleen mass (mg) / body weight (g).

[0096] Detection of serum biochemical indicators in D mice Blood was collected from the orbital cavity of mice, serum was separated, and the levels of serum IgE, TNF-α, IL-6, and IL-1β were measured according to the ELISA kit instructions.

[0097] Preparation of E mouse skin tissue pathological sections a. Fix the right ear and a portion of the back skin in 4% paraformaldehyde, respectively; b. Preparation of paraffin sections: fixation, dehydration, clearing, wax impregnation, embedding, sectioning, mounting, baking, dewaxing, and rehydration; c. Hematoxylin-eosin staining (HE); Immunohistochemical level detection of skin in F mice Dewaxing After baking paraffin sections of mouse skin tissue at a constant temperature for 100 minutes, the sections were immediately removed and placed in a first xylene solution for dewaxing for 10 minutes, and then transferred to a second xylene solution for dewaxing for 10 minutes.

[0098] Gradient ethanol washing After removing the sections from the xylene solution, they were soaked in 100% anhydrous ethanol, 95% anhydrous ethanol, 80% anhydrous ethanol, and 70% anhydrous ethanol for 6 minutes each. Finally, the mouse skin tissue sections were placed in PBS solution and gently shaken twice for 6 minutes each time.

[0099] Antigen thermal repair Take a 1000ml beaker and place mouse skin tissue sections in citrate antigen retrieval solution, ensuring the solution completely covers the tissue sections. Then, microwave the beaker on medium heat until boiling, maintaining boiling for 20 minutes for antigen thermal retrieval. During this process, carefully monitor the level of the antigen retrieval solution in the beaker to ensure all sections are fully submerged. After allowing the solution to cool naturally to room temperature, gently shake and wash the sections twice on a shaker, 6 minutes each time.

[0100] Inactivation of endogenous peroxidase Add an appropriate amount of endogenous peroxidase inhibitor (3% H2O2) to the sliced ​​skin tissue using a pipette, ensuring full coverage of the sample. Incubate at room temperature in the dark for 10 minutes, then gently shake and wash twice, each time for 6 minutes.

[0101] Closed Add 5% BSA blocking solution to the skin tissue, ensuring that the tissue edges are also fully covered by the blocking solution, and incubate at room temperature for 30 minutes.

[0102] Incubating antibodies Dilute the primary antibody appropriately with 5% BSA, add 200 μl of the diluted primary antibody to each skin tissue section, and then place the sections in a humidified chamber and incubate overnight at 4 °C in a laboratory refrigerator. After the primary antibody incubation, the skin tissue sections are gently washed three times with PBS on a shaker for 2 minutes each time the following day.

[0103] After washing, add secondary antibody (enhanced enzyme-labeled goat anti-mouse / rabbit IgG polymer) to the tissue samples and incubate at 37°C for 90 minutes. After incubation, gently wash the skin tissue sections three times with PBS on a shaker for 2 minutes each time.

[0104] DAB color development of slices Prepare fresh DAB staining solution and store it in an EP tube protected from light. Gently drop the DAB staining solution along the edge of the skin tissue and develop the stain at room temperature for 3-5 minutes, avoiding drying the slide. After DAB staining, gently rinse with double-distilled water to stop the DAB staining process, and then observe the staining under a microscope.

[0105] Hematoxylin staining, blueing, dehydration, and clearing Add an appropriate amount of hematoxylin to the slide using a 200 μl pipette for nucleus staining. The counterstaining time is approximately 30 to 40 seconds. Immediately after the hematoxylin counterstaining is complete, gently wash with water for 3 minutes. Then, differentiate with 1% hydrochloric acid alcohol for 3 seconds, followed by immersion in double-distilled water for 5 minutes. After rinsing, place the slide in 70% anhydrous ethanol, 80% anhydrous ethanol, 95% anhydrous ethanol, 100% anhydrous ethanol, and xylene in a second container for 3 minutes each.

[0106] Covering and Image Acquisition The slides were mounted with neutral resin and then air-dried in a fume hood for 2 hours. The staining of the mouse skin tissue samples was then observed and images were acquired under a fluorescence inverted microscope.

[0107] G Statistical processing Same as Experiment 1.

[0108] 2. Results 2.1 The therapeutic effect of white peony essential oil cream on skin lesions in DNCB-induced dermatitis model mice On day 3 after administration of DNCB, the skin on the back of mice in the DNCB-induced model group initially showed infiltrative erythema, edema, and itching after stimulation, followed by erosion, dryness, scaling, and crusting. The skin of mice in the blank group showed normal skin without significant changes.

[0109] On day 17 of the animal experiment, compared with the model group, skin lesions such as rash, erythema, and crusting were reduced in all groups. After the end of treatment on day 17, the skin on the backs of mice in the blank group grew well, was light red in color, and showed no obvious erythema, papules, or crusting; in the model group, the skin on the backs of mice was dark red, with papules, erythema, and crusting; in the 1% and 3% groups, the skin on the backs of mice was reddish, with a small amount of crusting; in the control and 5% groups, no obvious erythema, papules, or crusting were observed on the backs of mice. Figure 7 .

[0110] 2.2 Effect of Baiqing essential oil cream on ear allergy score in DNCB-induced dermatitis model mice The ear allergies of mice were scored after the last administration. Data from 6 groups were analyzed. P The values ​​all follow a normal distribution and also satisfy the property of homogeneity of variance. P>0.05), therefore, one-way ANOVA was used to compare the mean auricular scores of the six groups of mice. The results showed that, compared with the blank group, the model group mice had very obvious erythema, edema and scratch marks, and their auricular allergy scores were significantly increased. P <0.01). Compared with the model group, the auricular allergy scores of different concentrations of white peony essential oil cream and the control group were all reduced ( P <0.01), indicating that both improved eczema in mice to some extent. See Table 11.

[0111] Table 11. Comparison of ear allergy scores among different groups of mice (`x±s, n=7) 2.3 Effects of Baiqing essential oil cream on spleen index in mice with chronic eczema By comparing spleen indices, the effect of Baiqing essential oil cream on immune response can be preliminarily evaluated. (6 groups of data) P The values ​​all follow a normal distribution and also satisfy the property of homogeneity of variance. P >0.05), therefore one-way ANOVA was used. The results showed that the spleen index of the model group mice was significantly increased compared with the blank group ( P <0.01); compared with the model group, the 5% group reduced the spleen index in mice ( P <0.05), the control group significantly reduced the spleen index in mice ( P <0.01); there was no difference in spleen index between the 1% and 3% groups and the model group ( P >0.05); there was no difference in spleen index among the concentration groups ( P >0.05). The results showed that both the 5% group and the control group could reduce the spleen index of eczema mice, indicating that the 5% white peony oil cream has an immunosuppressive effect. See Table 12.

[0112] Table 12. Effects of Baiqing essential oil cream on spleen weight in mice of different groups (x±s, n=7) 2.4 Pathological manifestations of skin lesions on the backs of mice in each group Compared with the control group, the model group mice showed increased epidermal thickness, inflammatory cell infiltration in the dermis, and significant infiltration around glands. After treatment with the control group and the 1%, 3%, and 5% groups, the epidermal thickness and inflammatory cell infiltration in the dermis of the mice decreased. Figure 8 H&E staining results of the skin of mice in each group showed that the control group, 1%, 3%, and 5% of mice could repair the skin lesions of mice treated with DNCB.

[0113] 2.5 Effect of Baiqing essential oil cream on serum IgE levels in DNCB-induced dermatitis model mice Effects of Baiqing essential oil cream on serum IgE levels in mice: Compared with the blank group, the serum IgE content in the model group was significantly increased ( P <0.01); compared with the model group, the 5% group and the control group could reduce the serum IgE content in eczema mice ( P <0.05); compared with the control group, the 1%, 3%, and 5% groups showed no difference in their ability to reduce serum IgE levels in eczema mice ( P >0.05); there was no difference in serum IgE levels among the different concentration groups. P >0.05). The results showed that both the 5% group and the control group significantly reduced the serum IgE content in mice with eczema, indicating that the 5% white peony oil cream has an anti-allergic effect. See Table 13.

[0114] Table 13. Serum IgE levels in mice of each group (n=7) [M(Q1,Q3)] 2.6 Effects of Baiqing essential oil cream on serum IL-6, IL-1β, and TNF-α levels in DNCB-induced dermatitis model mice The p-values ​​of all 6 groups of data follow a normal distribution and also satisfy the homogeneity of variance. P Since the variance was greater than 0.05, one-way ANOVA was chosen. See Table 14.

[0115] Effect of Baiqing essential oil cream on serum IL-6 levels in mice: Compared with the blank group, the serum IL-6 level in the model group mice was significantly increased ( P <0.01); compared with the model group, the control group and each concentration group significantly reduced the serum IL-6 content in eczema mice ( P <0.01). This suggests that all treatment groups have anti-inflammatory effects. Compared with the control group, there was no difference in serum IL-6 in the 5% group of mice ( P >0.05), there was a significant difference in serum IL-6 levels between the 1% and 3% groups of mice ( P <0.01), indicating that the 1% and 3% styrax essential oil creams were less effective than hydrocortisone in inhibiting IL-6 in eczema mice, while the 5% styrax essential oil cream was comparable to hydrocortisone in inhibiting IL-6 in eczema mice. Compared with the 1% and 3% groups, the 5% group significantly reduced the serum IL-6 level in eczema mice ( P <0.01), indicating that 5% white sage oil cream has a better anti-inflammatory effect than other concentrations.

[0116] Effect of Baiqing essential oil cream on serum IL-1β levels in mice: Compared with the blank group, the serum IL-1β level in the model group mice was significantly increased ( P <0.01); compared with the model group, the control group and each concentration group significantly reduced the serum IL-1β level in eczema mice ( P<0.01). This indicates that all treatment groups have anti-inflammatory effects. Compared with the control group, there was no difference in serum IL-1β in the 5% group mice ( P >0.05), there was a significant difference in serum IL-1β between the 1% and 3% groups of mice ( P <0.01), indicating that 1% and 3% styrax essential oil creams were less effective than hydrocortisone in inhibiting IL-1β in eczema mice, while 5% styrax essential oil creams were comparable to hydrocortisone in inhibiting IL-1β in eczema mice.

[0117] Compared with the 1% and 3% groups, the 5% group significantly reduced the serum IL-1β level in eczema mice. P <0.01), indicating that the 5% white peony essential oil cream has the best anti-inflammatory effect among the three concentrations.

[0118] Effects of Baiqing essential oil cream on serum TNF-α levels in mice: Compared with the blank group, the serum TNF-α level in the model group mice was significantly increased ( P <0.01); compared with the model group, the control group, 1%, 3%, and 5% groups all significantly reduced the serum TNF-α content in eczema mice ( P <0.01). This indicates that all treatment groups have anti-inflammatory effects. Compared with the control group, the serum TNF-α levels in the 5% group of mice were significantly different ( P <0.05), there was a significant difference in serum TNF-α between the 1% and 3% groups of mice ( P <0.01), indicating that the 1%, 3%, and 5% white peony oil creams were less effective than hydrocortisone in inhibiting TNF-α in eczema mice. Compared with the 1% and 3% groups, the 5% group significantly reduced the serum TNF-α content in eczema mice ( P <0.01), indicating that the 5% white peony essential oil cream has the best anti-inflammatory effect among the three concentrations.

[0119] Table 14. Serum IL-6, IL-1β, and TNF-α levels in mice of each group (x±s, n=7) To more intuitively observe the distribution and content of IL-6, IL-1β, and TNF-α in mouse epidermis, immunohistochemical staining was performed.

[0120] It was observed that the distribution and levels of IL-6, IL-1β, and TNF-α in the epidermis of mice in the model group were increased, while the levels of IL-6, IL-1β, and TNF-α in the epidermis of the 5% group and the control group were lower than those in the model group. Figure 9 ).

[0121] Compared with the 1% and 3% groups, the 5% group significantly reduced the levels of IL-6, IL-1β, and TNF-α in the serum of eczema mice. P<0.01), indicating that the 5% white peony essential oil cream has a better anti-inflammatory effect than other concentrations.

[0122] In summary, white peony essential oil cream can achieve anti-allergic and anti-inflammatory effects by reducing the levels of IgE, IL-6, IL-1β, and TNF-α. It can effectively improve the skin lesions in a DNCB-induced mouse dermatitis model, with 5% white peony essential oil cream showing the best efficacy.

[0123] In summary, the above experiments show that: Baiqing essential oil creams of various concentrations can improve the clinical EASI scores of patients with mild to moderate chronic eczema due to blood deficiency and wind-dryness. Among these, 5% Baiqing essential oil cream has a better therapeutic efficacy than the positive control drug hydrocortisone butyrate (Eucerin). All concentrations of Baiqing essential oil creams can improve the itching intensity of patients with mild to moderate chronic eczema due to blood deficiency and wind-dryness, improve their quality of life, and reduce transepidermal water loss at the lesion site, with 5% Baiqing essential oil cream showing the best effect. During the treatment, there were no abnormal changes in patients' blood routine tests, liver and kidney function. Baiqing essential oil cream is safe for clinical application with few adverse reactions, demonstrating good efficacy and safety in treating chronic eczema due to blood deficiency and wind-dryness. Furthermore, all concentrations of Baiqing essential oil cream can improve the skin lesions in a DNCB-induced mouse dermatitis model, with 5% Baiqing essential oil cream showing the best effect. 5% Baiqing essential oil cream can reduce the skin lesions in the DNCB-induced mouse dermatitis model by decreasing the levels of allergy and inflammation in mice.

[0124] Therefore, the white peony essential oil cream of this invention is suitable for treating mild to moderate chronic eczema with blood deficiency and wind-dryness syndrome (long course of disease, recurrent attacks, dark skin lesions or pigmentation, severe itching, or rough and thickened skin lesions, often accompanied by dry mouth without thirst, poor appetite and abdominal distension. Pale tongue, white coating, and weak and thready pulse). It has good therapeutic effects.

[0125] The above-disclosed embodiments are merely specific examples of the present invention. However, the present invention is not limited thereto, and any variations that can be conceived by those skilled in the art should fall within the protection scope of the present invention.

Claims

1. A white cyanin essential oil composition for treating chronic eczema, characterized in that: It includes artemisia annua essential oil and white tea essential oil; the mass ratio of artemisia annua essential oil to white tea essential oil is (1-5):

1.

2. The white peony essential oil composition according to claim 1, characterized in that: It comprises artemisia annua essential oil and white tea essential oil; the mass ratio of artemisia annua essential oil to white tea essential oil is 4:

1.

3. The white peony essential oil composition according to claim 1 or 2, characterized in that: The white peony essential oil composition also includes petrolatum.

4. The white peony essential oil composition according to claim 3, characterized in that: It is a cream made from artemisia annua essential oil, white tea essential oil and petrolatum; the mass percentage of artemisia annua essential oil and white tea essential oil in the cream is 1~10%.

5. The white peony essential oil composition according to claim 4, characterized in that: It is a cream made from artemisia annua essential oil, white tea essential oil and petrolatum; the mass percentage of artemisia annua essential oil and white tea essential oil in the cream is 5%.

6. A method for preparing the white peony essential oil composition according to any one of claims 1 to 5, characterized in that: It includes the following steps: mixing artemisia oil, white tea oil, and petroleum jelly.

7. Use of the white peony essential oil composition according to any one of claims 1 to 5 in the preparation of a medicament for treating chronic eczema.

8. The use according to claim 7, characterized in that: The aforementioned medication is for treating chronic eczema due to blood deficiency and wind-dryness.

9. The use according to claim 7 or 8, characterized in that: The chronic eczema mentioned is mild to moderate chronic eczema.

10. The use according to claim 7 or 8, characterized in that: The drug is a moisturizing, anti-inflammatory, and / or anti-allergic drug.

Images